U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H27FN2O2
Molecular Weight 334.4283
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESMETHOXYFALLYPRIDE

SMILES

COC1=C(C=C(CCCF)C=C1)C(=O)NC[C@@H]2CCCN2CC=C

InChI

InChIKey=VPBJNBUDASILSQ-INIZCTEOSA-N
InChI=1S/C19H27FN2O2/c1-3-11-22-12-5-7-16(22)14-21-19(23)17-13-15(6-4-10-20)8-9-18(17)24-2/h3,8-9,13,16H,1,4-7,10-12,14H2,2H3,(H,21,23)/t16-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H27FN2O2
Molecular Weight 334.4283
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 17:31:08 UTC 2023
Edited
by admin
on Sat Dec 16 17:31:08 UTC 2023
Record UNII
CJD4EF9EME
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DESMETHOXYFALLYPRIDE
Common Name English
BENZAMIDE, 5-(3-FLUOROPROPYL)-2-METHOXY-N-((1-(2-PROPENYL)-2-PYRROLIDINYL)METHYL)-, (S)-
Systematic Name English
DMFP
Common Name English
5-(3-FLUOROPROPYL)-2-METHOXY-N-(((2S)-1-(2-PROPEN-1-YL)-2-PYRROLIDINYL)METHYL)BENZAMIDE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID301031714
Created by admin on Sat Dec 16 17:31:08 UTC 2023 , Edited by admin on Sat Dec 16 17:31:08 UTC 2023
PRIMARY
WIKIPEDIA
Desmethoxyfallypride
Created by admin on Sat Dec 16 17:31:08 UTC 2023 , Edited by admin on Sat Dec 16 17:31:08 UTC 2023
PRIMARY
PUBCHEM
10404663
Created by admin on Sat Dec 16 17:31:08 UTC 2023 , Edited by admin on Sat Dec 16 17:31:08 UTC 2023
PRIMARY
FDA UNII
CJD4EF9EME
Created by admin on Sat Dec 16 17:31:08 UTC 2023 , Edited by admin on Sat Dec 16 17:31:08 UTC 2023
PRIMARY
CAS
166173-81-5
Created by admin on Sat Dec 16 17:31:08 UTC 2023 , Edited by admin on Sat Dec 16 17:31:08 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
ANTAGONIST
TARGET -> INHIBITOR
ANTAGONIST